The white paper announces five new technologies in the field of life sciences. Our institute has launched two studies

Release time:


Since the first observation of cells by Dutch scientists in the 17th century, to the emergence of genetics, the discovery of DNA and the application of genetic engineering technology, life science has gradually become one of the indispensable and important subjects in the development of modern science and technology. In the 21st century, life science research has entered a new stage, bringing more possibilities and opportunities to human development.

Recently, the "2022 Life Sciences Annual Innovation White Paper" was released, explaining the latest development trends in the five major subdivisions of life sciences:

1. Smart experiment: digital technology helps reduce costs and increase efficiency throughout the entire process



Medical laboratories perform disease diagnosis, treatment and prevention by conducting biological, microbiological, immunological, chemical, blood immunological, hematological, biophysical, cytological, pathological or other tests on materials from the human body. , while helping to develop new drugs, new treatments and new technologies.

With the support of digital technologies such as the Internet, Internet of Things, big data, cloud computing and artificial intelligence, domestic laboratories have begun to iteratively upgrade to digitalization and intelligence, such as replacing highly repetitive mechanical manual operations with automated equipment, and through information construction Digitize laboratory information to avoid manual recording errors, and use AI to provide efficient data analysis and decision support.

2. Brain Science: Pay equal attention to brain-computer interface and diagnosis and treatment of brain diseases



Brain science has always been a popular R&D field in global life science application scenarios. According to Artery Network statistics, among the 43 national key laboratories in my country, 4 focus on brain science, with research areas ranging from brain cognition to brain-inspired technology. Among them, brain cognition research accounts for 70%, brain protection research accounts for 27%, and brain creation (brain-inspired research, brain-computer interface, etc.) research accounts for 3%.

It is generally believed that invasive brain-computer interface is an important direction for future development, which requires the use of neurosurgery to implant acquisition electrodes into the cerebral cortex, epidural or subdural. Its basic research has been translated into clinical applications, promoting innovative treatments for brain diseases and neuropathy by domestic companies.

3. Regenerative medicine



Regenerative medicine refers to the use of multidisciplinary theories and methods such as life sciences, engineering, and computer science to integrate materials science, cell technology, tissue engineering technology, genetic engineering technology and other modern bioengineering technologies to achieve repair, replacement and enhancement of human body. Technology for damaged, diseased or defective tissues and organs in the body.

According to FDA statistics, about 20% of human tissues currently have commercializable regenerative medicine products. Another 70% of human organ cells and scaffold regenerative medicine products have entered Phase II or above clinical trials. It is expected that in the next 10 years, more than half of human tissues and single organs, such as kidneys, blood vessels, pancreas, etc., will have commercialized products.

From the perspective of industrial practice, the regenerative medicine industry is mainly divided into three major directions: biological regenerative materials, stem cell repair and regenerative organs.

4. Organoids: Initial breakthrough in application boundaries

Organoids are miniature organs formed by three-dimensional culture of tissue stem cells such as embryonic stem cells and pluripotent induced stem cells in vitro. They are highly consistent with the source tissue in terms of tissue structure, cell type and function. They are useful for basic biomedical research, drug development and clinical practice. Precision medicine provides an ideal model.

In August 2022, the FDA approved the world's first new drug based on preclinical data obtained from organ-on-chip research to enter clinical trials, opening up the regulatory link for the application of organoids in new drug research and development, and further increasing the attention of the organoid track.

5. Precision medication: Entering into application markets such as hospitals and pharmaceutical companies



Precision medicine is a new medical model that uses molecular diagnostic technology to obtain genetic information, and combines proteomics, metabolomics and clinical data to deeply understand the causes, pathological stages and drug metabolism of diseases to achieve personalized treatment.

Among them, companion diagnosis is an important part of precision medicine. It is an in vitro diagnostic technology that can detect the therapeutic response of relevant patients to specific therapeutic drugs and helps identify patient groups who can benefit from a certain therapeutic product. thereby improving treatment outcomes and reducing health care costs. As relevant policies accelerate and are refined, companion diagnostics are rapidly entering the application market that is closer to clinical use, such as hospitals and pharmaceutical companies.

Our hospital has entered the field of life sciences and has carried out 2 studies

Shandong Yinfeng Life Sciences Research Institute focuses on the forefront of life sciences and is committed to the research and development of cutting-edge technologies in the fields of cellular medicine, immunology, cryogenic biomedicine, genetics and regenerative medicine. It has launched the Yinfeng Life Extension Plan and is committed to the cryopreservation of tissues and organs. He has been working on resuscitation research and human body cryopreservation and resuscitation research for many years.





Based on existing research results, our hospital carries out research on tissue engineering materials and 3D bioprinting technology. Using placenta, umbilical cord, etc. as raw materials, we use decellularization, freeze-drying, liquid nitrogen grinding, enzyme treatment and other methods to form various types of tissues of different shapes. Engineering matrix materials, and allogeneic decellularized tissue engineering materials are used to prepare bio-inks, and 3D printing is used to achieve rapid, accurate, and customized clinical research and application of soft tissue filling, with a view to developing bio-regenerative materials and achieving organ regeneration.



At the same time, Shandong Yinfeng Life Sciences Research Institute and the University of Science and Technology of China jointly carry out basic research to build an efficient cryogenic cryopreservation solution for organoids and an organoid function and damage assessment system to provide a foundation for organoid banking and applications.

In addition, Yinfeng Gene Technology Research Institute has achieved preliminary results in personalized drug susceptibility testing of tumor organoids. It has completed the development of personalized drug susceptibility testing of gastric cancer, colorectal cancer, and breast cancer tumor organoids to guide tumor patients in the precise use of drugs. , reduce patient pain.

Thanks to the rapid advancement of modern artificial intelligence, brain-computer interface, gene editing and other technologies, people have more tools to decode life, and it has also opened up a broader space for imagination to explore the field of life sciences. With the guidance, participation and assistance of countless experts like Chairman Zhao Gang and cryogenic biomedicine across the country, we believe that relevant research results and applications will have an important positive impact and contribution to human health and life.

Latest developments

The theme publicity activity of "Central Media Look at Jinan - Entering Jinan's Private Economy" was held in Yinfeng Biotechnology Park

On August 23, the Jinan Private Economic Development Bureau and China Economic Weekly jointly launched the theme publicity activity of "Central Media Look at Jinan - Entering Jinan's Private Economy" in Yinfeng Biotechnology Park.

Yinfeng Cryogenic and Anhui Medical University "Ministry of Education Engineering Research Center" project was accepted and awarded by the Ministry of Education

Led by Anhui Medical University and participated by Yinfeng Cryogenic Medical Technology Co., Ltd., the "Engineering Research Center for Life Resources Conservation and Artificial Organs of the Ministry of Education" was officially accepted and awarded by the Ministry of Education. As one of the four major platforms for the transformation of the center's project, Yinfeng Cryogenic Co., Ltd. is responsible for the "development, promotion and application of cryogenic preservation technology of biological matrix materials".

The inaugural meeting of the International Alliance for Life Extension Research was successfully concluded

On March 28, 2023, the kick-off meeting of the International Alliance for Life Extension Research was held in Jinan, Shandong. The "International Alliance for Life Extension Research" was initiated by Shandong Yinfeng Life Science Research Institute, and jointly established by 13 international scientific research institutions engaged in the field of cryogenic biomedicine from North America, Europe, Oceania, etc., and appeared at the conference through online and offline forms.